ZP4: A Potential Drug Target and Biomarker for Eye Diseases (G57829)

Target Name: ZP4

NCBI ID: G57829

Content of Review Report on ZP4 Target / Biomarker

ZP4

Other Name(s): zona pellucida glycoprotein 4 | Zona pellucida B protein | Zona pellucida protein B | ZP1B | Zona pellucida sperm-binding protein 4 | ZPB | zona pellucida protein B | ZPB2 | ZP4_HUMAN | Processed zona pellucida sperm-binding protein 4 | ZBP | Zona pellucida glycoprotein 4 | ZP1 | Zp-4

ZP4: A Potential Drug Target and Biomarker for Eye Diseases

Zona Pellucida Glycoprotein 4 (ZP4) is a protein that is expressed in the zona pellucida (ZP) of the retina, which is the outermost layer of the eye. ZP4 is a component of the ZP complex, which is responsible for maintaining the structure and function of the retina. ZP4 has been identified as a potential drug target and has been shown to play a role in several diseases, including age-related macular degeneration (AMD), diabetic retinopathy, and cataracts.

The ZP4 protein is composed of 199 amino acid residues and has a calculated molecular weight of 21.9 kDa. It is expressed in the ZP and is responsible for the structural integrity of the ZP complex. The ZP4 protein has a unique structure that includes a long N-terminus, a catalytic domain, and a C-terminus that is involved in interactions with other proteins.

ZP4 has been shown to be involved in several important physiological processes in the eye. For example, ZP4 plays a role in maintaining the structure and function of the retina, and has been shown to be involved in the regulation of cell proliferation and differentiation. It is also involved in the development and maintenance of the retinal blood vessels, and has been shown to play a role in the regulation of blood flow to the retina.

In addition to its role in maintaining the structure and function of the retina, ZP4 has also been shown to be involved in the development and progression of several eye diseases. For example, ZP4 has been shown to be involved in the development of age-related macular degeneration (AMD), which is the most common cause of blindness in the developed world. AMD is a progressive disease that is characterized by the gradual loss of cells from the retina, and is caused by the buildup of waste material in the retina.

ZP4 has also been shown to be involved in the development and progression of diabetic retinopathy, which is a type of retinal disease that is caused by the buildup of waste material in the retina. Diabetic retinopathy is a leading cause of blindness in people with diabetes, and is characterized by the gradual loss of cells from the retina.

In addition to its involvement in eye diseases, ZP4 has also been shown to be involved in other physiological processes in the body. For example, ZP4 has been shown to play a role in the regulation of cell signaling, and has been shown to be involved in the development and maintenance of the retinal blood vessels. It is also involved in the regulation of inflammation, and has been shown to play a role in the development of several inflammatory diseases, including uveitis and diabetic ketoacidosis.

Despite its involvement in several important physiological processes, ZP4 has not yet been shown to be a drug target. However, studies have shown that ZP4 can be targeted by small molecules, and that it is a good candidate for drug development. For example, several studies have shown that ZP4 can be inhibited by small molecules, and that this can result in the regression of ZP4-positive retinal samples in animal models of AMD.

In addition to its potential as a drug target, ZP4 is also a potential biomarker for several eye diseases. For example, ZP4 has been shown to be involved in the regulation of cell signaling in the retina, and has been shown to be involved in the development and progression of several eye diseases. This makes it a potential biomarker for these diseases, and could be used as a diagnostic tool in combination with other tests.

Overall, ZP4 is a protein that is expressed in the ZP of the retina and is involved in several important physiological processes in the eye. Its unique structure and its involvement in several important physiological processes make it a potential drug target and a good candidate for

Protein Name: Zona Pellucida Glycoprotein 4

Functions: Component of the zona pellucida, an extracellular matrix surrounding oocytes which mediates sperm binding, induction of the acrosome reaction and prevents post-fertilization polyspermy. The zona pellucida is composed of 3 to 4 glycoproteins, ZP1, ZP2, ZP3, and ZP4. ZP4 may act as a sperm receptor

The "ZP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets